Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition associated
with type 2 diabetes (T2DM) and cardiovascular disease (CVD). Since systemic metabolic …

The complex interplay between the gut microbiota, the intestinal barrier, the immune system
and the liver is strongly influenced by environmental and genetic factors that can disrupt the …

Simple Summary Non-alcoholic fatty liver disease (NAFLD) is a widespread disease
associated with metabolic disorders, such as obesity. In recent years, there has been …

Background Dietary interventions targeting the gut microbiota have been proposed as
innovative strategies to improve obesity-associated metabolic disorders. Increasing physical …

Aberration of the “gut-liver axis” contributes to the development and progression of
metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we use multi-omics …

To evaluate the changes in the gut microbiota associated with changes in the biochemical
markers of nonalcoholic fatty liver disease (NAFLD) after a lifestyle intervention with the …

Numerous studies show a modification of the gut microbiota in patients with obesity or
diabetes. Animal studies have also shown a causal role of gut microbiota in liver metabolic …

Liver transplantation (LT) is currently the only curative treatment option for selected patients
with end stage liver disease or hepatocellular carcinoma. Improving waiting list-mortality …

Appendicular lean mass (ALM) associates with mobility and bone mineral density (BMD).
While associations between gut microbiota composition and ALM have been reported …

Background Cardiovascular disease (CVD) is the single biggest contributor to global
mortality. CVD encompasses multiple disorders, including atherosclerosis, hypertension …